Avelas Biosciences is a company in the clinical-stage biotechnology sector and a trailblazer in the domain of intraoperative fluorescent cancer imaging. The firm is dedicated to the advancement of pegloprastide (also known as AVB-620), an innovative drug-device combination product intended for application in cancer surgery. Pegloprastide is formulated to enhance surgery by identifying cancer in real time and holds the potential to become a fundamental aspect of treatment for various cancer surgeries. Apart from breast cancer, Avelas intends to investigate the application of pegloprastide in a subset of other cancer surgeries, such as ovarian, colorectal, head and neck, melanoma, and sarcoma.